Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers

S Okumura, PA Jänne - Clinical cancer research, 2014 - AACR
Mutations in RAS oncogenes are frequently observed in human cancers, and the mutations
result in activation of the RAS–RAF–MEK–ERK pathway, leading to cell proliferation and …
被引用次数：32 相关文章

Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers

S Okumura, PA Jänne - … research: an official journal of the …, 2014 - pubmed.ncbi.nlm.nih.gov
Mutations in RAS oncogenes are frequently observed in human cancers, and the mutations
result in activation of the RAS-RAF-MEK-ERK pathway, leading to cell proliferation and …

[引用][C] Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers

S OKUMURA, PA JÄNNE - Clinical cancer research (Print), 2014 - pascal-francis.inist.fr
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant
Cancers CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.

S Okumura, PA Jänne - … Cancer Research: an Official Journal of the …, 2014 - europepmc.org
Mutations in RAS oncogenes are frequently observed in human cancers, and the mutations
result in activation of the RAS-RAF-MEK-ERK pathway, leading to cell proliferation and …
[PDF] archive.org

[PDF][PDF] Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers

S Okumura, PA Jänne - Clin Cancer Res, 2014 - scholar.archive.org
Mutations in RAS oncogenes are frequently observed in human cancers, and the mutations
result in activation of the RAS–RAF–MEK–ERK pathway, leading to cell proliferation and …

[引用][C] Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers

S OKUMURA, PA JÄNNE - Clinical …, 2014 - American Association for Cancer …